Search

Your search keyword '"Chung, Hyun C"' showing total 5 results
Start Over Author "Chung, Hyun C" Database Supplemental Index
5 results on '"Chung, Hyun C"'

1. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Author

Shitara, Kohei, Özgüroğlu, Mustafa, Bang, Yung-Jue, Di Bartolomeo, Maria, Mandalà, Mario, Ryu, Min-Hee, Fornaro, Lorenzo, Olesiński, Tomasz, Caglevic, Christian, Chung, Hyun C, Muro, Kei, Goekkurt, Eray, Mansoor, Wasat, McDermott, Raymond S, Shacham-Shmueli, Einat, Chen, Xinqun, Mayo, Carlos, Kang, S Peter, Ohtsu, Atsushi, Fuchs, Charles S, Lerzo, Guillermo, O'Connor, Juan Manuel, Mendez, Guillermo Ariel, Lynam, James, Tebbutt, Niall, Wong, Mark, Strickland, Andrew, Karapetis, Chris, Goldstein, David, Vasey, Paul, Van Laethem, Jean-Luc, Van Cutsem, Eric, Berry, Scott, Vincent, Mark, Muller, Bettina, Rey, Felipe, Zambrano, Angela, Guerra, Joaquin, Krogh, Merete, Baeksgaard, Lene, Yilmaz, Mette, Elme, Anneli, Magi, Andrus, Auvinen, Paivi, Alanko, Tuomo, Moehler, Markus, Kunzmann, Volker, Seufferlein, Thomas, Thuss-Patience, Peter, Goekkurt, Eray, Hoehler, Thomas, Haag, Georg, Al-Batran, Salah-Eddin, Castro, Hugo, Lopez, Karla, Aguilar Vasquez, Mynor, Sandoval, Mario, Lam, Ka On, Cuffe, Sinead, Kelly, Cathy, Geva, Ravit, Shacham-Shmueli, Einat, Hubert, Ayala, Beny, Alex, Brenner, Baruch, Giuseppe, Aprile, Falcone, Alfredo, Maiello, Evaristo, Passalacqua, Rodolfo, Montesarchio, Vincenzo, Hara, Hiroki, Chin, Keisho, Nishina, Tomohiro, Komatsu, Yoshito, Machida, Nozumo, Hironaka, Shuichi, Satoh, Taroh, Tamura, Takao, Sugimoto, Naotaoshi, Cho, Haruhiko, Omuro, Yashushi, Kato, Ken, Goto, Masahiro, Hyodo, Ichinosuke, Yoshida, Kazuhiro, Baba, Hideo, Esaki, Taito, Furuse, Junji, Wan Mohammed, Wan Zamaniah, Hernandez Hernandez, Carlos, Casas Garcia, Juan, Dominguez Andrade, Adriana, Clarke, Katriona, Hjortland, Geir, Glenjen, Nils, Kubiatowski, Tomasz, Jacek, Jassem, Wojtukiewicz, Marek, Lazarev, Sergey, Lancukhay, Yuri, Afanasayev, Sergey, Moiseyenko, Vladimir, Kostorov, Vladimir, Protsenko, Svetlana, Shirinkin, Vadim, Sakaeva, Dina, Fadeeva, Natalia, Yong, Wei Peng, Ng, Chau Hsien Matthew, Robertson, Barbara, Rapaport, Bernardo, Cohen, Graham, Dreosti, Lydia, Ruff, Paul, Jacobs, Conrad, Landers, Gregory, Szpak, Waldemar, Roh, Sang-Young, Lee, Jeeyun, Kim, Yeul Hong, Bang, Yung-Jue, Chung, Hyun Cheol, Ryu, Min-Hee, Alsina Maqueda, Maria, Longo Munoz, Federico, Cervantes Aguilar, Andres, Aranda Aguilar, Enrique, Garcia Alfonso, Pilar, Rivera, Fernando, Feliu Batle, Jaime, Pazo Cid, Roberto, Yeh, Kun-Huei, Chen, Jen-Shi, Chao, Yee, Yen, Chia-Jui, Özgüroğlu, Mustafa, Kara, Oguz, Yalcin, Suayib, Hochhauser, Daniel, Chau, Ian, Benson, Al, Shankaran, Veena, Shaib, Walid, Philip, Philip, Sharma, Vivek, Siegel, Robert, Sun, Weijing, Wainberg, Zev, George, Ben, Bullock, Andrea, Myrick, Samuel, Faruol, Josephine, Siegel, Richard, Larson, Timothy, Becerra, Carlos, Ratnam, Suresh, Richards, Donald A., and Riche, Stephen L.

Abstract

Patients with advanced gastric or gastro-oesophageal junction cancer that progresses on chemotherapy have poor outcomes. We compared pembrolizumab with paclitaxel in patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine.

Published
2018
Full Text
View/download PDF

2. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Author

Hecht, J. Randolph, Yung-Jue Bang, Qin, Shukui K., Chung, Hyun C., Xu, Jianming M., Park, Joon O., Jeziorski, Krzysztof, Shparyk, Yaroslav, Hoff, Paulo M., Sobrero, Alberto, Salman, Pamela, Jin Li, Protsenko, Svetlana A., Wainberg, Zev A., Buyse, Marc, Afenjar, Karen, Houe, Vincent, Garcia, Agathe, Kaneko, Tomomi, and Yingjie Huang

Published
2016
Full Text
View/download PDF

3. Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer...

Author

Yeo, Winnie, Chung Hyun C., Chan, Stephen L., Wang, Ling Z., Lim, Robert, Picus, Joel, Boyer, Michael, Mo, Frankie K. F., Koh, Jane, Rha, Sun Y., Hui, Edwin P., Jeung, Hei C., Roh, Jae K., Yu, Simon C. H., To, Ka F., Tao Qian, Ma, Brigette B., Chan, Anthony W. H., Tong, Joanna H. M., and Erlichman, Charles

Published
2012
Full Text
View/download PDF

4. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Author

Bang, Yung-Jue, Van Cutsem, Eric, Feyereislova, Andrea, Chung, Hyun C, Shen, Lin, Sawaki, Akira, Lordick, Florian, Ohtsu, Atsushi, Omuro, Yasushi, Satoh, Taroh, Aprile, Giuseppe, Kulikov, Evgeny, Hill, Julie, Lehle, Michaela, Rüschoff, Josef, and Kang, Yoon-Koo

Abstract

Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer.

Published
2010
Full Text
View/download PDF

5. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma

Author

Jeung, Hei C., Rha, Sun Y., Noh, Sung H., Min, Jin S., Kim, Byung S., and Chung, Hyun C.

Abstract

The authors evaluated the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) plus doxorubicin in gastric carcinoma after D2-3 curative resection. They also evaluated the effect of dose-related factors (delivered total dose/m2, actual dose intensity [ADI], relative dose intensity [RDI]) of this regimen on patient survival. A total of 301 patients with Stage II to IV (en bloc resected T4b; 1984 American Joint Committee on Cancer staging) were accrued between 1984 and 1996. Chemotherapy was started within 4 weeks of surgery according to the following schedule: intravenous bolus injection of doxorubicin 40 mg/m2 every 3 weeks for 12 cycles and 5-FU 400 mg/m2 weekly for 60 weeks. The toxicity and survival were evaluated. The median follow-up duration was 58 months. Sixty-four percent of the total patients and 71.7% of the patients who did not experience recurrence during the chemotherapy finished the protocol completely with acceptable toxicities. The 5- and 10-year disease free survival rates of total 301 patients were 58.4% and 46.5%, and the overall survival rates were 62.1% and 50.5%, respectively. Treatment completion group showed survival benefit over the early termination group in 5-year survival (75.2% vs. 52.9%; P = 0.0005). The median ADI of 5-FU and doxorubicin were 349 and 11 mg/m2/week, and the median RDIs of 5-FU and doxorubicin were 0.87 and 0.83, respectively. Multivariate analysis demonstrated that completion of chemotherapy is an independent prognostic factor of both disease free and overall survival. However, ADI and RDI did now show any effect on survival. Adjuvant chemotherapy with 5-FU plus doxorubicin for 60 weeks after D2-3 dissection induced promising survival duration with acceptable toxicities. Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma. Cancer 2001;91:2016–25. © 2001 American Cancer Society.

Published
2001
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results